Daily Respiratory Research Analysis
Mechanistic and translational advances in respiratory science stood out today: structural elucidation of the MERS coronavirus E viroporin defines a druggable ion-channel target; a randomized controlled exposure trial links subway particulate exposure to acute declines in lung function and heightened inflammation; and a mechanistic PNAS study shows mycophenolic acid can paradoxically foster fitter SARS-CoV-2 variants under immunosuppression despite antiviral effects. Together, these papers span a
Summary
Mechanistic and translational advances in respiratory science stood out today: structural elucidation of the MERS coronavirus E viroporin defines a druggable ion-channel target; a randomized controlled exposure trial links subway particulate exposure to acute declines in lung function and heightened inflammation; and a mechanistic PNAS study shows mycophenolic acid can paradoxically foster fitter SARS-CoV-2 variants under immunosuppression despite antiviral effects. Together, these papers span antiviral target discovery, environmental respiratory risk, and within-host viral evolution.
Research Themes
- Viroporins and structural antiviral targets in respiratory viruses
- Environmental particulate exposure and acute respiratory effects
- Immunosuppression, antiviral pharmacology, and within-host viral evolution
Selected Articles
1. Ion channel structure and function of the MERS coronavirus E protein.
This study determines both the membrane-bound structure and single-channel conductance of the MERS-CoV E (envelope) protein, demonstrating that it forms a K+-conducting ion channel (viroporin). Defining the structural basis of channel activity positions E as a concrete antiviral target for small-molecule channel blockers.
Impact: First structural-functional definition of MERS E viroporin provides a rational template for antiviral inhibitor design against a high-mortality coronavirus. It advances mechanistic understanding of coronavirus virulence.
Clinical Implications: E protein channel blockers could represent a novel antiviral class; structural information enables structure-guided screening. While immediate clinical change is unlikely, this work prioritizes E-targeted drug discovery and preclinical testing.
Key Findings
- Determined the membrane-bound structure of the MERS-CoV E protein.
- Measured single-channel conductance showing that MERS E forms a K+-conducting ion channel.
- Established E as a drug-targeted viroporin implicated in coronavirus virulence.
Methodological Strengths
- Integration of structure determination with single-channel electrophysiology.
- Direct study of membrane-bound protein conformation and function.
Limitations
- Lack of in vivo validation linking channel inhibition to reduced virulence.
- Abstract provides limited quantitative details (e.g., exact conductance values).
Future Directions: Screen and optimize small-molecule E channel blockers; evaluate antiviral efficacy in cell and animal models; assess conservation and druggability across coronavirus E proteins.
Coronavirus envelope (E) proteins form drug-targeted ion channels that cause virulence to infected cells. The Middle East respiratory syndrome (MERS) virus has high mortality rates, but its E structure and function are unknown. We report the single-channel conductance and structure of membrane-bound MERS E protein. MERS E conducts K
2. Impacts of subway air particles on healthy adults: a randomized controlled trial in a Chinese city.
In an RCT of 80 healthy adults randomized to 2 hours/day on a subway platform versus office for five consecutive days, repeated subway particle exposure led to acute reductions in lung function and increases in respiratory and systemic inflammatory markers. Platform pollutant levels were substantially higher, including fine particulate matter and associated constituents.
Impact: Provides randomized evidence linking short-term subway PM exposure to measurable decrements in lung function and inflammation, informing urban public health and transit policies.
Clinical Implications: Clinicians should consider subway exposure as a potential trigger of respiratory symptoms and transient lung function decline, particularly in susceptible individuals; public health measures (ventilation/filtration upgrades, exposure advisories) may mitigate risk.
Key Findings
- Randomized exposure to subway platform air for 2 hours/day over 5 days reduced lung function in healthy adults.
- Repeated exposure increased respiratory and systemic inflammatory markers compared with office control.
- Subway platform pollutant levels (e.g., fine particulate matter) were significantly higher than office air.
Methodological Strengths
- Randomized controlled exposure design with repeated daily sessions.
- Concurrent environmental monitoring and physiological/inflammatory assessments.
Limitations
- Short exposure window (5 days) and healthy adult population limit generalizability to vulnerable groups.
- Single-city setting may not capture variability across transit systems.
Future Directions: Assess longer-term and cumulative effects, include susceptible populations (e.g., asthma, COPD), and test engineering controls (ventilation/filtration) to reduce exposure and health impacts.
BACKGROUND: Subway systems reduce traffic congestion, air pollution, and carbon dioxide emissions in cities but the impacts of subway air pollution on the health of subway users remain obscure. We conducted a randomized controlled trial involving 83 healthy adults, with 80 included in the final analysis, randomly grouped to spend 2 h daily for 5 consecutive days either in an office or on a subway platform. The fine (PM RESULTS: The subway platform exhibited significantly high pollutant levels, with mean PM CONCLUSIONS: This study provides the first evidence that repeated exposure to subway airborne particles is associated with reduced lung function and increased respiratory and systemic inflammation in healthy adults. Our results underscore the need to develop strategies to mitigate exposure risks, ultimately protecting public health in urban environments.
3. Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants.
MPA suppresses SARS-CoV-2 replication via depletion of cellular GTP pools but can select breakthrough variants carrying S P812R, ORF3 Q185H, and E S6L. The combined mutations confer higher fitness (faster replication, higher titers, earlier cytopathic effects) without conferring MPA resistance, and host transcriptional dysregulation precedes breakthrough.
Impact: Reveals a clinically relevant paradox: an immunosuppressant with antiviral activity can drive emergence of fitter SARS-CoV-2 variants in vitro. This underscores the need for vigilant surveillance and therapeutic strategy adjustments in immunosuppressed patients.
Clinical Implications: Transplant and immunosuppressed patients on MPA may warrant enhanced virologic monitoring and consideration of antiviral combinations to minimize within-host selection of fitter variants. Infection control and genomic surveillance should prioritize this population.
Key Findings
- MPA inhibits SARS-CoV-2 replication by depleting cellular GTP pools.
- Breakthrough variants with S P812R, ORF3 Q185H, and E S6L emerge under MPA, showing accelerated replication and higher titers without MPA resistance.
- Host transcriptional dysregulation under MPA precedes breakthrough mutation emergence.
Methodological Strengths
- Mechanistic linkage of antiviral effect to GTP depletion with identification of specific breakthrough mutations.
- Integration of virologic phenotyping with host transcriptomic profiling.
Limitations
- Predominantly in vitro with no clinical patient outcome data.
- Fitness advantages were shown in culture; transmissibility and clinical impact require in vivo validation.
Future Directions: Prospective genomic surveillance in MPA-treated cohorts, evaluation of antiviral combinations to prevent variant emergence, and in vivo validation of mutation fitness and pathogenicity.
Mycophenolic acid (MPA) is commonly used in immunosuppressive regimens following solid organ transplantation. We demonstrate that MPA treatment reproducibly inhibits the replication of a range of viruses, including severe respiratory syndrome coronavirus 2 (SARS-CoV-2). Mechanistically, we identified cellular guanosine triphosphate pool depletion as a key mediator of this antiviral effect. Strikingly, this inhibition can be overcome which was correlated with the emergence of three breakthrough mutations in the SARS-CoV-2 genome (S P812R, ORF3 Q185H, and E S6L). Subsequent analyses confirmed that the combination of these mutations conferred accelerated replication kinetics, higher viral titers, and more rapid onset of cytopathic effects, but not MPA resistance. Comparison of global transcriptional responses to infection highlighted dysregulation of specific cellular gene programs under MPA treatment prior to breakthrough mutation emergence. Together, these findings identify viral and host drivers of variant emergence under immunosuppression. They also advocate for close monitoring of immunosuppressed patients, where emergence of novel viral variants with a fitness advantage may arise.